Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 18/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755242 | 0.88 | CCR5 (0.61) | CCR5KCNH2 | |
| SCHEMBL6705234 | 0.78 | CCR5 (0.85) | CCR5 | |
| SCHEMBL6703964 | 0.78 | KCNH2 (0.79) | CCR5KCNH2 | |
| SCHEMBL6704348 | 0.78 | CCR5 (0.83) | CCR5 | |
| SCHEMBL6701709 | 0.75 | CCR5 (0.69) | CCR5KCNH2 | |
| SCHEMBL6703484 | 0.75 | CCR5 (0.79) | CCR5 | |
| Hydrochloric Acid SCHEMBL6704564 | 0.75 | CCR5 (0.77) | CCR5 | |
| SCHEMBL6298721 | 0.74 | CCR5 (0.60) | CCR5KCNH2 | |
| SCHEMBL6702100 | 0.74 | CCR5 (0.71) | CCR5KCNH2 | |
| SCHEMBL6298538 | 0.73 | CCR5 (0.55) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960602-B2 | A N-[1-(N-carbonyl-2-aminoethyl)-4-piperidinyl]-acetamides derivatives, as immunomodulators, antiinflammatory agents, for treating rheumatoid arthritis, respiratory system disorders, skin disorders; chemical intermediates | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1373205-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076948-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110794-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CXCR1 | CCR5 1/4885KCNH2 1850/4885CYP3A4 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.